Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Brufsky

Showing results (11-20 of 192) with videos related to

Pageof 20
Sort By:
Oncology (Williston Park, N.Y.)|January 18, 2015
Bisphosphonates in breast cancer: a triple winner?Aju Mathew, Adam Brufsky
The Breast Journal|January 20, 2019
Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use?Natalie Klar, Adam Brufsky
Oncology (Williston Park, N.Y.)|May 30, 2009
Bevacizumab in breast cancer: the best is yet to come?Shannon Puhalla, Adam Brufsky
The Lancet. Oncology|February 28, 2017
Less is more? De-intensification of therapy for early-stage HER2-positive breast cancerAju Mathew, Adam Brufsky
Annals of Translational Medicine|July 5, 2023
Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progressionJulia Foldi, Adam Brufsky
Hematology/Oncology Clinics of North America|August 7, 2013
How to develop and deliver pathway-based careAdam Brufsky, Kathleen Lokay
Journal of the National Cancer Institute|November 7, 2019
Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter?Adam Brufsky, Aju Mathew
International Journal of Cancer|May 15, 2014
Bisphosphonates in breast cancerAju Mathew, Adam Brufsky
JAMA Network Open|February 21, 2025
Toward Optimization of Post-CDK4/6 Inhibitor TherapyJulia Foldi, Adam Brufsky
Annals of Internal Medicine|January 20, 2015
Bisphosphonates do not reduce breast cancer in postmenopausal womenAju Mathew, Adam Brufsky
Pageof 20

Showing results (11-20 of 192) with videos related to

Sort By:
Pageof 20
Oncology (Williston Park, N.Y.)|January 18, 2015
Bisphosphonates in breast cancer: a triple winner?Aju Mathew, Adam Brufsky
The Breast Journal|January 20, 2019
Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use?Natalie Klar, Adam Brufsky
Oncology (Williston Park, N.Y.)|May 30, 2009
Bevacizumab in breast cancer: the best is yet to come?Shannon Puhalla, Adam Brufsky
The Lancet. Oncology|February 28, 2017
Less is more? De-intensification of therapy for early-stage HER2-positive breast cancerAju Mathew, Adam Brufsky
Annals of Translational Medicine|July 5, 2023
Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progressionJulia Foldi, Adam Brufsky
Hematology/Oncology Clinics of North America|August 7, 2013
How to develop and deliver pathway-based careAdam Brufsky, Kathleen Lokay
Journal of the National Cancer Institute|November 7, 2019
Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter?Adam Brufsky, Aju Mathew
International Journal of Cancer|May 15, 2014
Bisphosphonates in breast cancerAju Mathew, Adam Brufsky
JAMA Network Open|February 21, 2025
Toward Optimization of Post-CDK4/6 Inhibitor TherapyJulia Foldi, Adam Brufsky
Annals of Internal Medicine|January 20, 2015
Bisphosphonates do not reduce breast cancer in postmenopausal womenAju Mathew, Adam Brufsky
Pageof 20